Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
David J GibsonMark G WardClarissa RentschAntony B FriedmanKirstin M TaylorMiles Patrick SparrowPeter R GibsonPublished in: Alimentary pharmacology & therapeutics (2020)
Evidence for exposure-response relationship is stronger for infliximab than adalimumab. Due to heterogeneity in settings for drug level measurements, therapeutic ranges vary. These factors need to be taken into account when interpreting the evidence and extending this to therapeutic strategies for IBD patients.
Keyphrases
- ulcerative colitis
- patients with inflammatory bowel disease
- end stage renal disease
- rheumatoid arthritis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- prognostic factors
- single cell
- patient reported outcomes
- molecularly imprinted
- solid phase extraction
- drug induced
- simultaneous determination